We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
Read MoreHide Full Article
Key Takeaways
Revvity agreed to acquire HCD, adding human cell models for metabolic disease research.
HCD's EndoC-BetaH5 model supports studies of beta cell biology in diabetes and obesity.
The HCD acquisition is expected to be closed in fourth-quarter 2026, pending approvals.
Revvity, Inc. (RVTY - Free Report) recently announced that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio, strengthening its capabilities in drug discovery, screening and preclinical research for metabolic disease therapies, including GLP-1-targeting treatments.
Per management, HCD’s differentiated human cell models complement Revvity’s technologies supporting drug discovery and development. Combining HCD’s cell models with the company’s screening, detection, automation and analysis capabilities is expected to provide more integrated and human-relevant solutions as researchers seek improved approaches to understanding human biology.
RVTY Stock Trend Following the News
RVTY stock has lost 2.3% since the announcement on Wednesday. Year to date, the stock has gained 25% compared with the industry’s 1.5% growth and the S&P 500’s 10.3% rise.
The acquisition of HCD is expected to strengthen Revvity’s growth prospects by expanding its position in human-relevant life sciences tools and metabolic disease research. The combination of HCD’s specialized cell models with Revvity’s established detection, cell analysis and screening technologies could create opportunities to support next-generation therapies and broaden customer relationships across the research-to-clinic continuum.
RVTY currently has a market capitalization of $13.82 billion.
Image Source: Zacks Investment Research
More on the News
HCD brings to Revvity its flagship EndoC-βH5 human pancreatic beta cell model, which is designed to help researchers study beta cell biology and function in areas such as diabetes and obesity. The company’s offerings also include specialized media and reagents, preclinical research capabilities, and its proprietary NatLine platform for developing reliable and functionally consistent human cell models.
The acquisition complements Revvity’s detection and cell analysis capabilities, as EndoC-βH5 cells can be paired with Revvity’s HTRF and AlphaLISA assays to measure pharmacological markers such as cAMP and insulin, as well as pHSense technology for receptor internalization studies. The cells may also be used with ATPlite assays to evaluate cell viability and proliferation.
Together with Revvity’s high-content screening platform, these capabilities could enable researchers to generate and interpret complex cellular data. As wet-lab validation gains importance in AI-enabled science, human-relevant cell models can help researchers validate AI-derived findings.
Beyond early-stage drug discovery, HCD’s technology can support regenerative medicine research for Type 1 diabetes and quality-control activities as cell-based therapies advance toward commercialization. The transaction is expected to be closed in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.
Factors Working in Favor of the Market
According to data provided by Grand View Research, the global cell analysis market is estimated to be valued at $37.3 billion in 2026 and is expected to witness a CAGR of 11.7% through 2033.
Factors like the growing number of drug discovery activities, increasing prevalence of chronic diseases, rising pharmaceutical and biotechnology R&D investments and advancements in cell analysis technologies are supporting the market’s growth. The increasing adoption of high-content screening, single-cell analysis and advanced cellular profiling is also expected to drive demand for sophisticated cell-based research tools.
Other News
Last month, Revvity launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex will initially be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
Key Takeaways
Revvity, Inc. (RVTY - Free Report) recently announced that it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio, strengthening its capabilities in drug discovery, screening and preclinical research for metabolic disease therapies, including GLP-1-targeting treatments.
Per management, HCD’s differentiated human cell models complement Revvity’s technologies supporting drug discovery and development. Combining HCD’s cell models with the company’s screening, detection, automation and analysis capabilities is expected to provide more integrated and human-relevant solutions as researchers seek improved approaches to understanding human biology.
RVTY Stock Trend Following the News
RVTY stock has lost 2.3% since the announcement on Wednesday. Year to date, the stock has gained 25% compared with the industry’s 1.5% growth and the S&P 500’s 10.3% rise.
The acquisition of HCD is expected to strengthen Revvity’s growth prospects by expanding its position in human-relevant life sciences tools and metabolic disease research. The combination of HCD’s specialized cell models with Revvity’s established detection, cell analysis and screening technologies could create opportunities to support next-generation therapies and broaden customer relationships across the research-to-clinic continuum.
RVTY currently has a market capitalization of $13.82 billion.
Image Source: Zacks Investment Research
More on the News
HCD brings to Revvity its flagship EndoC-βH5 human pancreatic beta cell model, which is designed to help researchers study beta cell biology and function in areas such as diabetes and obesity. The company’s offerings also include specialized media and reagents, preclinical research capabilities, and its proprietary NatLine platform for developing reliable and functionally consistent human cell models.
The acquisition complements Revvity’s detection and cell analysis capabilities, as EndoC-βH5 cells can be paired with Revvity’s HTRF and AlphaLISA assays to measure pharmacological markers such as cAMP and insulin, as well as pHSense technology for receptor internalization studies. The cells may also be used with ATPlite assays to evaluate cell viability and proliferation.
Together with Revvity’s high-content screening platform, these capabilities could enable researchers to generate and interpret complex cellular data. As wet-lab validation gains importance in AI-enabled science, human-relevant cell models can help researchers validate AI-derived findings.
Beyond early-stage drug discovery, HCD’s technology can support regenerative medicine research for Type 1 diabetes and quality-control activities as cell-based therapies advance toward commercialization. The transaction is expected to be closed in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.
Factors Working in Favor of the Market
According to data provided by Grand View Research, the global cell analysis market is estimated to be valued at $37.3 billion in 2026 and is expected to witness a CAGR of 11.7% through 2033.
Factors like the growing number of drug discovery activities, increasing prevalence of chronic diseases, rising pharmaceutical and biotechnology R&D investments and advancements in cell analysis technologies are supporting the market’s growth. The increasing adoption of high-content screening, single-cell analysis and advanced cellular profiling is also expected to drive demand for sophisticated cell-based research tools.
Other News
Last month, Revvity launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex will initially be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Key Picks
Currently, RVTY carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.